|
4 December 2024 |
New revision of Biochemistry Telephone Action Limits document (update to revision number but contents and telephoning policies have not changed). |
revision 2024.061 |
|
2 December 2024 |
Links to SE Genomic Hub pages updated for DNA/ genetic testing, haemochromatosis genetics, familial hypercholesterolaemia genetics, cystic fibrosis genetics, Gilbert syndrome genetic testing and Wilson disease genetic testing. |
revision 2024.060 |
|
26 November 2024 |
revision 2024.059 |
|
|
revision 2024.058 |
||
|
25 November 2024 |
Dr Sunil Sharma added to management contacts as Clinical Director. |
revision 2024.057 |
|
Update to serum methylmalonic acid - routine screening of requests. |
revision 2024.056 |
|
|
Plasma metadrenalines added. |
revision 2024.055 |
|
|
New revision of document "Actions For Clinical Teams and the Pathology Laboratory for VHF Investigations". |
revision 2024.054 |
|
|
18 November 2024 |
New request form for T-SPOT TB assay. |
revision 2024.053 |
|
13 November 2024 |
Update to IgM reference range (minor change for 1-19y males) from 18/11/24 |
revision 2024.052 |
|
New CSF lactate ranges. |
revision 2024.051 |
|
|
29 October 2024 |
Amendment to N‑Acetylcysteine interference cutoff for lactate (plasma). |
revision 2024.050 |
|
18 October 2024 |
New revisions of overnight dexamethasone suppression test, oral glucose tolerance test, growth hormone response to an oral glucose tolerance test and short synacthen test. |
revision 2024.049 |
|
2 October 2024 |
Management restructure - contacts updated as required. |
revision 2024.048 |
|
Update to drug interference listing for protein (urine) |
revision 2024.047 |
|
|
16 September 2024 |
Update to amiodarone (change to desethylamiodarone range). |
revision 2024.046 |
|
11 September 2024 |
Update to perhexiline sample type. |
revision 2024.045 |
|
2 September 2024 |
revision 2024.044 |
|
|
New revision of Biochemistry telephoning ranges (revision 21) |
revision 2024.043 |
|
|
7 August 2024 |
Updated content for voriconazole and posaconazole. |
revision 2024.042 |
|
6 August 2024 |
Urine catecholamines updated (change of analysing laboratory). |
revision 2024.041 |
|
Beta carotene updated (change of analysing laboratory). |
revision 2024.040 |
|
|
29 July 2024
|
POCT pages updated: see Point of care testing, POCT glucose testing and POCT blood gas analysis. |
revision 2024.039 |
|
New Factor VIIIc assays - see coagulation factor assays |
revision 2024.038 |
|
|
24 July 2024 |
For myeloproliferative neoplasm mutations and BCR-ABL - note additional time is required to process results when they are received, typically one to two weeks. Please contact the laboratory if you require a result to be processed urgently. |
revision 2024.037 |
|
16 July 2024 |
Addition of guidance to urine metadrenalines and 5-HIAA. |
revision 2024.036 |
|
10 July 2024 |
Information on Minimum Retesting Intervals added to request information for individual disciplines. |
revision 2024.035 |
|
revision 2024.034 |
||
|
8 July 2024 |
revision 2024.033 |
|
|
3 July 2024 |
Acylcarnitines sample requirements updated. |
revision 2024.032 |
|
Serum osmolality reference ranges updated. |
revision 2024.031 |
|
| 26 June 2024 |
Paediatric investigation profiles updated. |
revision 2024.030 |
| 19 June 2024 |
Minimum Repeat Interval (MRI) implementationWe would like to inform you that over the coming months Pathology is implementing guidelines issued by the Royal College of Pathologists (RCPath) relating to Minimum Repeat Intervals (MRI’s) for common laboratory tests. Pathology frequently receives repeat requests for certain tests that fall within RCPath minimum repeat intervals. When placing orders for pathology requests in the ICE Order Comms System, if a minimum repeat interval is triggered, a warning message will appear informing the requestor that a recent result is available for that test. It is recognised that in certain situations repeat testing, before the minimum repeat interval, would be appropriate and that guidelines cannot cover every clinical scenario. We ask that you consider if the repeat test being asked for really is required. If so, a legitimate repeat test reason should be entered on the ICE Order Comms system. Where appropriate, repeat tests will be cancelled and requestors will be redirected to the available result within the minimum repeat interval. These guidelines* have been reviewed by the RCPath Clinical Effectiveness Team, Lay Governance Group, and Special Advisory Committees. The remit of these guidelines is to improve the quality of the diagnostic service and enable optimum usage of finite laboratory resource. In addition, over the coming weeks you will also see some streamlining of profiles/test collections on ICE, e.g. LFTs in some profiles will be replaced by ALT only. In these situations, if you consider that a full LFT is also required it can be requested separately to the profile. The value of tests depends upon a variety of specific circumstances. Rapid repeats and unnecessary requesting are just two examples of low value, poor quality work that increases the cost of healthcare and creates additional work for the clinician, laboratory and many others, and results in blood loss, pain and time taken up for the patient. Diagnostics contribute approximately 10% of the healthcare's carbon emissions, help us to reduce harm, cost, work, and carbon emissions - think twice, and choose wisely. Thank you for your cooperation. |
revision 2024.029 |
| 11 June 2024 |
Updated adalimumab and infliximab content - no longer using Biogen forms. Requests can be made via ICE. |
revision 2024.028 |
| 4 June 2024 |
Updated CSF orexin reference ranges. |
revision 2024.027 |
| 21 May 2024 |
revision 2024.026 |
|
| 15 May 2024 |
Addition to Specimens, requests, reports - please note that due to the automated handling of many requests, instructions in clinical details fields on ICE forms (e.g. to add extra tests) will not be registered as test requests. |
revision 2024.025 |
| 30 April 2024 |
Addition of sample packaging/ transport information to Histopathology and Cellular Pathology pages. |
revision 2024.024 |
| 16 April 2024 |
Update to acylcarnitines - change of provider at referral lab. |
revision 2024.023 |
| 15 April 2024 |
Update to APTT and APTT ratio reference ranges (see coagulation screen ). |
revision 2024.022 |
| 8 April 2024 |
Reference range for urine metadrenalines has changed due to change of analysing laboratory. |
revision 2024.021 |
| 27 March 2024 |
LDL-cholesterol (part of lipid profile ) is now being calculated using the Sampson equation. |
revision 2024.020 |
| 18 March 2024 |
Point of care blood gas analysis training is now on IRIS. |
revision 2024.019 |
| 12 March 2024 |
Addition of test information to haemoglobin A1c. |
revision 2024.018 |
| 6 March 2024 |
Change to neonatal blood tubes - removed old information on these and outdated tube selection posters from specimens, requests, reports. |
revision 2024.017 |
|
DELAYS TO URINE STEROID PROFILE ANALYSIS The referral lab are unable to provide us with a date as to when normal service will resume, and due to this they are only processing very urgent requests that fall under the following criteria: If your request is for any of the above, please ensure this is stated very clearly on the request. If your request is NOT for any of the above, samples will be stored until reagent has arrived and backlog can begin to be cleared. If no clinical details are not provided, samples will be treated as non-urgent and stored as above. |
revision 2024.016 |
|
| 27 February 2024 |
Information on UKAS non-accredited tests added to Histopathology special investigations. |
revision 2024.015 |
|
Update to 25-hydroxyvitamin D with addition of link to NICE CKS. |
revision 2024.014 |
|
| 21 February 2024 |
Addition of potentially toxic range to amiodarone |
revision 2024.013 |
| 14 February 2024 |
Removal of old sample handling guidelines for suspected or confirmed COVID-19 patients. Old coronavirus news page has been depublished. |
revision 2024.012 |
| 13 February 2024 |
TPMT updated - only one EDTA blood sample required. |
revision 2024.011 |
| 6 February 2024 |
Fetal maternal haemorrhage - weekend referral site changed. |
revision 2024.010 |
| 5 February 2024 |
Procalcitonin no longer routinely available. |
revision 2024.009 |
| 30 January 2024 |
Addition of NICE CKS link to uric acid (serum) |
revision 2024.008 |
| 16 January 2024 |
Pathology supplies updated with link to ordering form on UHSussex public site. |
revision 2024.007 |
|
revision 2024.006 |
||
| 9 January 2024 |
TFT - added list of situations where fT4 should be requested. |
revision 2024.005 |
| 8 January 2024 |
Winpath Geriatric admission profile no longer in use. |
revision 2024.004 |
|
Turnaround updated time for factor V Leiden and prothrombin gene mutation updated. |
revision 2024.003 |
|
| Von Willebrand screening - activity is no longer being reported with blood group specific ranges. |
revision 2024.002 |
|
| Liza Faustino added as Head of Quality (interim). |
revision 2024.001 |
From the end of 2023:
|
6 December 2023 |
CSF biochemistry tests updated to include volume of CSF required. |
revision 2023.084 |
|
Update to NT-proBNP page (cutoffs in treated patients no longer cited by NICE). |
revision 2023.083 | |
|
5 December 2023 |
Abnormal LFT screen profile no longer in use - please request follow up tests as per local guidelines and clinical situation. |
revision 2023.082 |
|
New TFT reporting from December 2023: Routine TFT requests will get TSH as a first line screen. If the TSH is within the age specific reference interval only the TSH result will be analysed and reported. Free T4 will be added automatically if the TSH result is outside the reference interval and for all children (<18 years). Free T4 and free T3 can be requested individually if required. Please request fT4 if hypopituitarism is suspected or if the patient is pregnant. |
revision 2023.081 |